- Global Pharma News & Resources

Key Insights from FMIs Report on Prefilled Auto-Injectors Market

Anaphylactic shock is the most common chronic disease in Europe and North America region. Allergy UK says, approximately 20% of patients struggle with anaphylactic reaction in Europe. Anaphylactic shock requires adrenaline auto injector devices to be treated. Adrenaline auto injectors are sold under various brands, such as Emerade, Epipen and Jext in the UK. The global auto injectors market was valued at US$ US$ 1,700 Mn, in terms of value, in 2016, according to the latest research by Future Market Insights (FMI). The report on auto injectors further projects significant growth potential with average year-on-year growth rate of 15.1% through 2026.

Manufacturers in the auto-injectors market are working towards user-centric design approaches for the purpose of enhancing the ease-of-usage as well as to overcome the unwillingness that is related with the self-administration of the intramuscular injections. Increasing demand from the biologics developers are expected to create incremental opportunities for the auto-injectors market across the globe.

A renowned research firm after a thoroughgoing analysis reached on to declare few facts and figures relating to auto-injectors market. The report indicates that the auto-injectors market is likely to grow at 15.1% CAGR during forecast period, 2016-2026, for reaching an assessment of US$ 7,000Mn by 2026-end. The profiled players that are operating in the auto-injectors market includes Eli Lilly and Company, Janssen Global Services, LLC, Mylan N.V., Becton, Dickinson and Company, Amgen Inc., Sanofi and Antares Pharma, Inc.

Download a Sample Report with Table of Contents and Figures:

The profiled companies are expected to observe a noteworthy growth in the near future across the globe, which would be beneficial for the overall growth of auto-injectors market on a larger basis. Manufacturers with the profiled players are seen working keenly on strategic developments that is inclusive of expansion of the product portfolio, innovation as well as advancement of their existing and emerging products, which in due course will help in increasing the customer-base.

Novartis AG & Amgen Inc. Receive FDA Approval for their Migraine Prevention Drug

The profiled companies as well as manufacturers can note the point that Novartis AG and Amgen Inc. receive U.S. FDA approval for their migraine prevention drug meant for adults, namely Aimovig. Customers must on a larger basis take note of the point that this drug is considered as the first ever treatment that has been green-lighted by FDA for the purpose of prevention from migraines, thereby obstructing calcitonin gene-related peptide receptors. This receptor is expected to play a major role in the development of migraines.

Apart from all this, the main point to note is that Amgen Inc. will be highly benefitted with this auto-injector as it would help them with business expansion as well. The profiled companies as well as manufacturers in the auto-injectors market are taking immense efforts to increase the awareness with regards to auto-injectors across healthcare sector. Aimovig 70 is a SureClick auto-injector but the company also is working towards increasing the availability of Aimovig 140 due to surging demand from the customer-base for the same. Customers can take note of the point that current reimbursement environment will go hand in hand with the adoption of Aimovig.

For any Queries Linked with the Report, Ask an Analyst@

Key Segment

based on product type

  • Prefilled Auto-injectors
  • Fillable auto-injectors

based on distribution channel

  • Traditional sales channels
  • hospital pharmacies
  • retail pharmacies

based on regions

  • North America
  • Latin America
  • Europe
  • Asia Pacific Excluding Japan
  • Japan
  • MEA

Antares Pharma, Inc. Announced FDA Approval for Makena® Subcutaneous Auto-Injector

The profiled companies as well as manufacturers can note the point that Antares Pharma, Inc. recently had been mentioning that its parent company receives FDA approval for Makena® Subcutaneous auto-injector. The development of this product was with the help of QuickShot® device of Antares Pharma, Inc. This device helps in delivering rapid injection for the highly viscid drug products, through gauge nonvisible needle. Customers can note that this can be highly beneficial for the purpose of reducing risk of the preterm birth in the women that are pregnant with a single baby and had delivered a preterm baby earlier

Contact Sales for Further Assistance in Purchasing this Report@

Explore FMI’s Coverage of the Healthcare, Pharmaceuticals, and Medical Devices Industry

Microfluidics Market– Get insights on the global microfluidics market through FMI’s report covering detailed quantitative and qualitative analysis for projection period 2016-2026. 

Electronic Medical Records (EMR) Market– FMI’s exhaustive study on the electronic medical records (EMR) market covers the latest trends, innovations, key players, and popular strategies for the period 2015-2025. 

Clinical Trials Market– Obtain detailed analysis on the clinical trials market through FMI’s report covering competitive analysis, key regions, and segmental analysis. 

About Future Market Insights

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries:
For Media Enquiries:
Press Release Source:

Editor Details

Last Updated: 24-Mar-2021